A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas

William B. Pearse*, Adam M. Petrich, Leo I Gordon, Reem Karmali, Jane Norma Winter, Shuo Ma, Jason B Kaplan, Amir Behdad, Andreas Klein, Borko Jovanovic, Irene Helenowski, Sonali M. Smith, Andrew M. Evens, Barbara Pro

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas'. Together they form a unique fingerprint.

Medicine & Life Sciences